Coherus BioSciences (CHRS) Reports 24-Week Data from Phase Three Study of CHS-1420 to Treat Psoriasis
Tweet Send to a Friend
Coherus BioSciences, Inc. (NASDAQ: CHRS), today reported results from an ongoing 3-Part, Phase 3 clinical study of CHS-1420, an adalimumab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
